We recently published 12 Fresh Stocks Jim Cramer Discussed Along With His Latest Thoughts On Quantum Computing . DaVita Inc. (NYSE:DVA) is one of the stocks Jim Cramer recently discussed. DaVita Inc. (NYSE:DVA) is a healthcare company that caters to the needs of kidney patients. Cramer made these remarks after co-host Carl Quintanilla discussed the stock’s performance and commented that it was among a group that was “leading us lower”. Healthcare stocks were shaky as legislation in the Senate without the ...

Core Insights - DaVita Inc. is a kidney dialysis service provider valued at $9 billion, with earnings announcement for Q3 2025 expected on October 29 [1] - Analysts project a profit of $3.29 per share for Q3 2025, reflecting a 27% increase from $2.59 per share in the same quarter last year [2] - For the full fiscal year 2025, EPS is anticipated to be $10.93, a 12.9% rise from $9.68 in fiscal 2024, with further growth expected to $12.73 in fiscal 2026 [3] Performance Analysis - DaVita's stock has underperformed, declining 24% over the past 52 weeks, compared to a 13.5% gain in the S&P 500 Index and a 7.2% loss in the Health Care Select Sector SPDR Fund [4] - The company's disappointing performance is attributed to a year-over-year decline in normalized non-acquired treatment and pressure on adjusted operating margins [5] Recent Financial Results - In Q2, DaVita reported revenue of $3.4 billion, a 6.1% increase year-over-year, with adjusted EPS of $2.95, up 47.5% from the previous quarter [6] Analyst Ratings - The consensus rating for DaVita stock is "Hold," with one "Strong Buy," seven "Hold," and one "Moderate Sell" among nine analysts [7] - The average analyst price target for DaVita is $150.86, suggesting a potential upside of 20.4% from current levels [7]

Company Overview - DaVita Inc. (DVA) is valued at a market cap of $9.4 billion and provides kidney dialysis services for patients with chronic kidney failure, including outpatient, hospital inpatient, and home-based hemodialysis services, as well as clinical laboratory services [1] - The company is classified as a "mid-cap stock" due to its market cap exceeding $2 billion, highlighting its size and influence in the medical care facilities industry [2] Financial Performance - In Q2, DaVita reported total revenue of $3.4 billion, a 6.1% year-over-year increase, with dialysis patient service revenues growing by 4.8% [5] - The adjusted EPS for the quarter was $2.95, reflecting a 47.5% increase from the previous quarter, driven by strong margin expansions [5] - However, operating cash flow declined by 59.4% year-over-year to $324 million, and free cash flow fell 76% year-over-year to $157 million, negatively impacting investor sentiment [5] Stock Performance - DaVita's stock has decreased 27% from its 52-week high of $179.60, with a 4.2% decline over the past three months, underperforming the Nasdaq Composite's 17.2% return [3][4] - Over the past 52 weeks, DVA has fallen 20%, significantly lagging behind the NASX's 27% increase during the same period [4] - Year-to-date, shares of DVA are down 12.3%, compared to NASX's 18% rise [4] Competitive Position - DaVita has underperformed compared to its rival, Fresenius Medical Care AG (FMS), which has seen a 26.7% increase over the past 52 weeks and a 13.5% rise year-to-date [6] - Analysts maintain a cautious outlook on DaVita, with a consensus rating of "Hold" and a mean price target of $153.57, suggesting a 17.1% premium to its current price levels [6]

Company Performance - DaVita HealthCare (DVA) stock decreased by 3.26% to $132.26, underperforming the S&P 500 which gained 0.3% [1] - Over the past month, DVA shares increased by 3.51%, while the Medical sector rose by 7.07% and the S&P 500 by 2.09% [1] Financial Projections - DaVita is expected to report an EPS of $3.29, reflecting a growth of 27.03% year-over-year [2] - Revenue is forecasted to be $3.4 billion, indicating a 4.27% increase compared to the same quarter last year [2] Annual Estimates - For the fiscal year, earnings are projected at $10.93 per share and revenue at $13.46 billion, representing growths of 12.91% and 5.01% respectively from the previous year [3] - Recent analyst estimate revisions suggest a positive outlook for DaVita's business [3] Valuation Metrics - DaVita has a Forward P/E ratio of 12.51, which is lower than the industry average of 20.96 [6] - The company's PEG ratio stands at 0.98, compared to the industry average PEG ratio of 1.94 [6] Industry Context - The Medical - Outpatient and Home Healthcare industry is ranked 152 by Zacks, placing it in the bottom 39% of over 250 industries [7] - The Zacks Industry Rank indicates that top-rated industries outperform the lower-rated ones by a factor of 2 to 1 [7]